| Model Number |
MMT-442A |
| Medical Device Problem Code |
Leak/Splash (1354)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
08/10/2024
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
Reference number (b)(4).Event occurred in the united states.On (b)(6) 2024, it was reported that the patient faced infusion set had leakage at quick release site.The infusion set was in use for 2 to 3 days.No further information available.
|
| |
|
Additional Manufacturer Narrative
|
|
E1: patient city: (b)(6).Patient country: united states.
|
| |
|
Event or Problem Description
|
|
To date no additional patient or event details have been received.
|
| |
|
Additional Manufacturer Narrative
|
|
Correction: this mdr is being submitted to correct the submitted expiration date under d4 and manufacturing date under h4.Additional information - this mdr is being submitted to include the below: h6: investigation results under type of investigation, investigation findings, investigation conclusions.H11: investigation summary: complaint investigation results: a complaint investigation has been initiated under complaint investigation child record (b)(4).The batch 6003300.In question was manufactured at the osted site.Device history record (dhr) review: the 6003300 was manufactured according to the work instruction (wi) [79] appendix 1 batchcard for production of packaging room on 13-oct-2023 with a total of (b)(4) units.Review of the dhr showed that all relevant tests required during the related processes had been fulfilled and met the requirements.No deviation was identified, nor maintenance events were recorded related to complaint code.Test results: no product was returned.Conclusion summary of complaint investigation: as a result of the following, no non-conformance (nc) raised during production related to complaint code, no trend identified for the lot in question, no further actions are required.This complaint will not require further root cause investigation nor corrective and preventive action (capa) plan.Therefore, this issue will be monitored through the post market surveillance activities.
|
| |
|
Search Alerts/Recalls
|